Home > Oncology > ESMO 2021 > Genitourinary Cancer > Modified ipilimumab schedule reduces risk of grade 3/4 adverse events

Modified ipilimumab schedule reduces risk of grade 3/4 adverse events

Presented By
Dr Naveen Vasudev, St James University Hospital, UK
Conference
ESMO 2021
Trial
Phase 2, PRISM
First results of the randomised, phase 2 PRISM trial showed that ipilimumab every 12 weeks, instead of every 3 weeks, in combination with first-line nivolumab significantly reduced rates of grade 3/4 adverse events in patients with advanced renal cell carcinoma (RCC). Ipilimumab/nivolumab is an approved and standard first-line treatment for patients with intermediate and poor-risk advanced RCC. Ipilimumab/nivolumab has proven to significantly increase overall survival (OS) versus sunitinib in patients with intermediate or poor risk advanced RCC [1]. However, grade 3/4 treatment-related adverse events are relatively common during the initial combination period. Therefore, the randomised, phase 2 PRISM trial (EudraCT 2017-001476-33) aimed to determine whether modified scheduling of ipilimumab, in combination with nivolumab, is associated ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on